Compare APPF & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | BLCO |
|---|---|---|
| Founded | 2006 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | 2015 | 2022 |
| Metric | APPF | BLCO |
|---|---|---|
| Price | $179.52 | $16.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $286.78 | $18.45 |
| AVG Volume (30 Days) | 324.6K | ★ 340.4K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | $950,822,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $19.69 | $8.65 |
| Revenue Next Year | $16.70 | $5.59 |
| P/E Ratio | $152.39 | ★ N/A |
| Revenue Growth | ★ 19.72 | 6.47 |
| 52 Week Low | $142.56 | $13.09 |
| 52 Week High | $325.90 | $18.92 |
| Indicator | APPF | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 51.13 |
| Support Level | $144.97 | $14.62 |
| Resistance Level | $178.43 | $16.54 |
| Average True Range (ATR) | 6.01 | 0.45 |
| MACD | 1.02 | -0.04 |
| Stochastic Oscillator | 75.17 | 21.94 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.